Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Radiodermatitis × Radiotherapy × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 99 Lung Neoplasms 76 Lymphoma 72 Head and Neck Neoplasms 69 Glioblastoma 68 Breast Neoplasms 65 Rectal Neoplasms 62 Squamous Cell Carcinoma of Head and Neck 60 Esophageal Neoplasms 54 Prostatic Neoplasms 52 Leukemia 50 Central Nervous System Neoplasms 48 Pancreatic Neoplasms 47 Precursor Cell Lymphoblastic Leukemia-Lymphoma 43 Lymphoma, Non-Hodgkin 41 Hodgkin Disease 41 Lymphoma, Large B-Cell, Diffuse 39 Lymphoma, Follicular 38 Leukemia, Lymphocytic, Chronic, B-Cell 37 Colorectal Neoplasms 36 Esophageal Squamous Cell Carcinoma 35 Burkitt Lymphoma 35 Brain Neoplasms 35 Gliosarcoma 33 Lymphoma, Large-Cell, Immunoblastic 31 Adenocarcinoma Of Esophagus 30 Lymphoma, Mantle-Cell 28 Lymphoma, B-Cell, Marginal Zone 28 Neoplasms 25 Uterine Cervical Neoplasms 24

Interventions

calcipotriene 1 Triamcinolone Acetonide 1 Radiotherapy, Conformal 1 Radiotherapy 1 Melatonin 1 Dimethyl Sulfoxide 1 Curcumin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07192588 2025-09-25

GuARD

Graegis Pharmaceuticals Ltd

Phase 2 Active not recruiting

Breast Neoplasms, Radiodermatitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡